The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

Renal Failure

Volumn 36, Issue 8, 2014, Pages 1291-1297

  Matsuo, Akira ^a   Iida, Akio ^a   Tanimoto, Minako ^a   Matsushita, Mutsuyoshi ^a   Miyamoto, Ken Ichi ^b  

^a JAPAN TOBACCO INC   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Combined treatment; Comparison of efficacy; Ferric citrate hydrate; Phosphate binder; Phosphorus absorption

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CREATININE; FERRIC CITRATE HYDRATE; JTT 751; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; UNCLASSIFIED DRUG; FERRIC CITRATE; FERRIC ION; LANTHANUM;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG ACTIVITY; FECES ANALYSIS; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; HYPERPHOSPHATEMIA; IRON BLOOD LEVEL; IRON METABOLISM; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHORUS ABSORPTION REDUCING EFFECT; PRIORITY JOURNAL; RAT; RETICULOCYTE; URINALYSIS; URINARY EXCRETION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; INTESTINE ABSORPTION; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM CARBONATE; FERRIC COMPOUNDS; INTESTINAL ABSORPTION; LANTHANUM; MALE; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84906686801     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.930491     Document Type: Article

References (19)

1. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011; 7(10):578-589.
2. Kazama JJ. Oral phosphate binders: history and prospects. Bone. 2009;45(Suppl 1):s8-s12.
3. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-1277.
4. Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Int Suppl. 1999;73:s42-s45.
5. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in hemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002; 17(2):265-270.
6. Sinsakul M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121(1-2):c25-c29.
7. Umanath K, Sika M, Niecestro R, et al. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int. 2013; 17(1):67-74.
8. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478-487.
9. Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543-552.
10. Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial. 2005;9(1):11-15.
11. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009;4(1):178-185.
12. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium-and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997; 12(8):1640-1644.
13. Pennick M, Poole L, Dennis K, Smyth M. Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. Ren Fail. 2012;34(3):263-270.
14. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997;12(5):961-964.
15. Damment SJ. Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail. 2011;33(2):217-224.
16. Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37:346-358.
17. Nagano N, Miyata S, Obana S, et al. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron. 2001; 89(3):321-328.
18. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96(10):2818-2827.
19. Daugirdas JT, Finn WF, Emmett M, Chertow GM; Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial. 2011;24(1):41-49.